Loading
Led AZA-001, which showed azacitidine extends survival in high-risk MDS and made hypomethylating agents standard.
Pierre Fenaux (Hôpital Saint-Louis, Paris) was principal investigator of AZA-001, the trial that showed azacitidine improves overall survival compared with conventional care in higher-risk myelodysplastic syndromes, the first drug to do so and the foundation of hypomethylating therapy in MDS and AML. He co-led the European APL trials with Laurent Degos that established all-trans retinoic acid and leads the Groupe Francophone des Myélodysplasies.
| Title | Journal | Year |
|---|---|---|
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (AZA-001) | Lancet Oncology | 2009 |
| Myelodysplastic syndromes | Lancet | 2014 |
| IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed | The Lancet | 2024 |
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag mds.
Shares Cancer Institute AP-HP Nord, Université Paris Cité, Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag mds.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS).
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/